2014. IFX vs ADA

OL/IFX vs ADA/Postop recurrence CD

Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study

Prospective, open-label, randomized pilot study.
Patients with CD undergoing ileocolonic resection were randomised to IFX 5mg/kg (0,2,6 and q8w) or ADA (160/80 and 40 q2w). Treatment started within 4-6 weeks after surgery.
All patients received oral metronidazol 500mg BD for 2 weeks. No other drugs were permited.

Primary endpoints: Endoscopic, histological and clinical recurrence after 12 months of therapy.

Results: N=20
- Endoscopic recurrence: IFX 20%(n=2), ADA 10% (n=1), p=ns
- Histological recurrence: IFX 30% vs 20% ADA, p=ns

Conclusion:
IFX and ADA were similar in preventing histological, endoscopic and clinical recurrence after curative ileocolonic resection in high risk CD patients.



A: endoscopic recurrence; b: histological activity; C: clinical recurrence.

Fig. 1 Comparison of results between infliximab group (IFX) and adalimumab group (ADA) after 1 year of therapy

Tursi A et al. Tech Coloproctol.2014;18:1041–1046